-

Ultivue Announces New Executive Team Member

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ultivue announces the addition of Richard C. Malabre, CPA in the role of Chief Financial Officer, as the company adds to its growing executive team.

Richard is a seasoned financial professional with more than thirty years of experience in finance, accounting, internal audit, financial planning, and treasury roles. Richard was most recently the Vice President & Controller at Oxford Immunotec Global PLC a global diagnostic company, where he was responsible for the worldwide accounting, finance, and treasury functions during their initial public offering, three acquisitions, a divestiture and sale of the company. Prior to Oxford Immunotec, he held Controller and other senior financial roles at several medical device and high technology firms including Salient Surgical Technologies, Neurometrix, and Teradyne.

Richard holds an MS from the MIT Sloan School of Management and a BA in economics from Trinity College.

Richard joins Ultivue as the company completes its Series D round of funding and looks to strengthen its position as a market leader in multiplex immunofluorescence assays for digital pathology.

“This is a very exciting time to join the Ultivue team as we continue to accelerate our growth to support our customers as they solve complex therapeutic challenges,” says Richard.

“Richard carries with him the epitome of professionalism and experience,” notes Jacques Corriveau, President and CEO at Ultivue. “These are crucial traits to have in a financial partner as Ultivue looks toward its future as a mainstay in the market.”

About Ultivue:

Ultivue provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs.

Contacts

Mark Rees
Ultivue
mark.rees@ultivue.com

Ultivue


Release Versions

Contacts

Mark Rees
Ultivue
mark.rees@ultivue.com

Social Media Profiles
More News From Ultivue

Ultivue and ngTMA® Announce Collaborative Agreement to Provide Multiplex and Spatial Analysis for Clinical Research

CAMBRIDGE, Mass. & BERN, Switzerland--(BUSINESS WIRE)--Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies and, the Translational Research Unit (TRU) platform of University of Bern, that develops novel workflows for tissue microarray (ngTMA®) construction, announce a collaborative agreement to promote multiplexed immunofluorescence (mIF) assays and the use of next generation TMAs to unlock spatial analysis in scientific research...

Ultivue Announces AI Partner Ecosystem to Accelerate Analysis of Multiplex Immunofluorescence Image Data in Translational Medicine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ultivue, Inc., an industry leader in multiplexing assays and analytics solutions for tissue biomarker studies, announced today multiple collaborations for AI-powered spatial phenomics solutions for translational research groups and Biopharma. Ultivue develops unique workflows for use in both multiplex immunofluorescence (mIF) imaging and spatial phenomics. Its proprietary InSituPlex® technology is designed for fast and comprehensive exploration of biologically...

Ultivue Announces Co-Marketing and Co-Development Collaboration with Paige for AI-Powered Biomarker Imaging Solutions for Precision Medicine

CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ultivue, an industry leader in multiplexing tools for tissue biomarker analysis, and Paige, the global leader in AI-based diagnostic software in pathology, today announced a partnership to collaborate on the co-development and co-marketing of AI-powered spatial immunophenotype capabilities to pharmaceutical and research customers. Collaborative efforts will initially focus on the development of AI to enable improved understanding of the tumor microe...
Back to Newsroom